Since chemoresistance is responsible for an estimated 90% of deaths in patients with advanced‐stage gynecologic malignancies,50, 51, 52 the present study evaluated the ability of PDP, a non‐mechanistically overlapping therapeutic approach, in combination with low‐dose carboplatin to overcome PFAS‐induced platinum resistance in endometrial cancer cells. This evidence concerns the gene PDP1 and endometrial cancer.